Altimmune (ALT) recently released pemvidutide's 48-week topline results from their IMPACT Phase IIb trial, which revealed the drug's ability to continue improvement for several non-invasive fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback